Latka logo

Jared Seehafer

LinkedIn

GetLatka interview

How Enzyme Reached 21 Customers Helping Life Science Companies Navigate FDA Compliance (Interview with CEO Jared Seehafer)

Jared Seehafer (Co-Founder and CEO of Enzyme) spoke to Nathan Latka on December 3, 2018.

Enzyme figures from the interview

Customers (2018)
21
Team Size (2018)
8
Total Funding Raised (2018)
A couple million dollars
Investor
Y Combinator
“So we've got 21 companies that are using the platform in production of various sizes, everything from sort of product teams to the large organizations, enterprise organizations to, like I said, kind of a garage startup.”
“So we were in sort of quasi stealth, though I hate the term in 2017, launched the company earlier this year in 2018, Q1.”
“We went through Y Combinator Accelerator, did a small friends and family round, kind of just when I was just getting started. Then went through YC and then raised a seed stage round of capital, you know, through various VCs that are kind of in that, at that cohort right after YC.”

Read the interview →Watch the recording →

Bio

Jared Seehafer is the CEO and Cofounder of Enzyme, a software company that automates life science regulatory approval and compliance. He is a 12 year veteran of the medical device and biopharma industries, having worked or consulted at organizations ranging from Amgen, Abbott and Medtronic to seed-stage startups.

Company

Enzyme

South San Francisco, United States · Founded 2017

Revenue
$10.3M
Funding
$2M
Team size
33
Customers
21

Company profile →CEO interview →

Also at Enzyme